Graypoint LLC’s Corbus Pharmaceuticals CRBP Stock Holding History

Graypoint LLC’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-447	Closed	-$1.48K	–	357
2022 Q4	$1.48K	Hold	447	–	–	﹤0.01%	333
2022 Q3	$2K	Hold	447	–	–	﹤0.01%	318
2022 Q2	$3K	Hold	447	–	–	﹤0.01%	295
2022 Q1	$7K	Hold	447	–	–	﹤0.01%	316
2021 Q4	$8K	Hold	447	–	–	﹤0.01%	298
2021 Q3	$14K	Hold	447	–	–	﹤0.01%	275
2021 Q2	$25K	Buy	+447	New	+$24.8K	﹤0.01%	256

Other funds holding CRBP

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Graypoint LLC's CRBP Position: Q1 2023 in Review

Graypoint LLC sold out of Corbus Pharmaceuticals (CRBP) in Q1 2023, closing a stake of 447 shares — an estimated $1.48K sold.

Graypoint LLC first reported a position in CRBP in Q2 2021 and held it in 7 quarters. The position peaked at $25K in Q2 2021. 30 funds tracked by Wall St. Rank hold CRBP as of Q1 2023.

Graypoint LLC reported no remaining Corbus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Graypoint LLC sold 447 Corbus Pharmaceuticals shares in Q1 2023, an estimated $1.48K.
Graypoint LLC first reported a position in Corbus Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Graypoint LLC's Corbus Pharmaceuticals position peaked at $25K in Q2 2021.
30 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2023.

Based on Graypoint LLC's 13F filing for Q1 2023, filed 2 May 2023.